Compare Marvell Technology Inc (MRVL) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Smith & Nephew plc — how do they compare? Marvell Technology Inc trades at $222.44 (market cap $190.56B), while Smith & Nephew plc trades at $29.82 (market cap $12.54B). The key difference: Marvell Technology Inc is far larger — about 15.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| MRVL | SNN | |
|---|---|---|
Market Cap | $190.56B | $12.54B |
Sector | Technology | Health |
52-Week High | $316.43 | $38.70 |
52-Week Low | $62.31 | $28.73 |
Enterprise Value | $191.99B | $15.57B |
Dividend Yield | 0.11% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $221.15, up 6.04% today, reflecting strong momentum amid AI-driven optimism. The stock exhibits a bullish technical signal with moving averages supporting the uptrend, while recent earnings beats and a consensus analyst price target of $275.68 highlight fundamental strength. Key developments include partnerships with NVIDIA and Microsoft's Maia 300 AI accelerator, positioning MRVL for growth in data center and networking segments.
Outlook remains positive with AI infrastructure expansion driving revenue projections to $8.7B in 2026, though high valuation ratios (P/E 72.96) and supply chain risks warrant caution. Net income turned profitable in 2026 forecasts, but competitive pressures and market volatility pose challenges. Analyst consensus is strongly bullish with 82% buy ratings, suggesting upside potential if execution aligns with growth expectations.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
